Basic information Pharmacological effects Pharmacokinetics Clinical indications and usage Safety Related Supplier
ChemicalBook >  Product Catalog >  API >  Antibiotics >  Other antibiotic Drugs >  Posaconazole

Posaconazole

Basic information Pharmacological effects Pharmacokinetics Clinical indications and usage Safety Related Supplier
Posaconazole Basic information
Posaconazole Chemical Properties
  • Melting point:170-1720C
  • Boiling point:850.7±75.0 °C(Predicted)
  • Density 1.36±0.1 g/cm3(Predicted)
  • Flash point:9℃
  • storage temp. -20°C Freezer
  • pka14.72±0.20(Predicted)
  • form powder
  • color white to beige
  • optical activity[α]/D -24 to -32°, c = 1.0 in chloroform-d
  • Merck 14,7602
  • InChIKeyRAGOYPUPXAKGKH-XAKZXMRKSA-N
  • CAS DataBase Reference171228-49-2(CAS DataBase Reference)
Safety Information
Posaconazole Usage And Synthesis
  • Pharmacological effectsPosaconazole (posaconazole) is derived from itraconazole. It is currently subject to III phase clinical trials. Its pharmacological effects are similar with azoles, but compared with itraconazole, it has a stronger inhibitory effect on the C14 demethylation of steroid, especially for Aspergillus.
  • PharmacokineticsStudies on dosage and dosage protocol have shown that the rate of absorption and elimination rate is in line with the single-compartment model. There are significant differences on the relative bioavailability of different doses of oral suspension. It can be taken separately (every 12 hours or every 6 hours) which can significantly improve the bioavailability with the protein binding rate of 98% to 99%. With respect to tablets, the bioavailability of suspensions increase and food can significantly improve the speed and extent of absorption of drug absorption. An investigation of renal dysfunction on the pharmacokinetics of the drug study results has showed that the drug can’t be removed by hemodialysis without being affected by hemodialysis. Single-dose study has showed that patients with varying degrees of chronic kidney disease have no necessity for dosage adjustment. The Half-life of this is about 25 hours which can be primarily metabolized by the liver.
  • Clinical indications and usageIt can be clinically used for the treatment of aspergillosis, zygnmycosis, and fusariumsis and can also be used for infection caused by part of fluconazole-resistant Candida genus. Studies have shown that posaconazole can widely and effectively applied to the treatment of phaeohyphomycosis and improve the infection survival rate of dermatitidis infection in a dose-dependent manner. The drug, as second-line drugs, has an effective rate of 44% to 78% against the invasive aspergillosis which is resistant to amphotericin B and itraconazole. It also has an effective rate of 71% against the zygomycete fungi. The drug is an oral suspension with the recommended dose of 200mg and 4 times per day with meals and taken orally for 7 to 10 days. This dose can also be maintained or changed to 400mg with oral administration of 2 times per day. The steady-state plasma concentration can reach within 7 to 10 days.
    The above information is edited by the Chemicalbook of Dai Xiongfeng.
  • DescriptionPosaconazole, launched in the UK, is the newest member of the azole class of antifungal agents to reach the market. It is indicated for the treatment and prophylaxis of a range of invasive fungal infections, including aspergillosis,fusariosis, chromoblastomycosis, mycetoma, and coccidiomycosis in patients who are refractory to, or intolerant of, standard therapy with amphotericin B and/or itraconazole. In the US, it is approved for the prophylaxis of invasive Aspergillus and Candida infections in patients 13 years of age who are at high risk of developing these infections due to being severely immunocompromised. Additionally, it is approved for the treatment of oropharyngeal candidiasis. Posaconazole has an expanded spectrum of activity over other members of the azole antifungals. In addition to potent activity against refractory cases of aspergillosis and fluconazole-resistant Candida, it demonstrates activity against Zygomycetes.
  • Chemical PropertiesWhite Solid
  • OriginatorSchering-Plough (US)
  • UsesOrally active triazole antifungal.
  • UsesPosaconazole is a sterol C14ɑ demethylase inhibitor with an IC50 of 0.25 nM
  • DefinitionChEBI: An N-arylpiperazine that consists of piperazine carrying two 4-substituted phenyl groups at positions 1 and 4. A triazole antifungal drug.
  • brand nameNoxafil
  • Antimicrobial activityThe spectrum includes dimorphic fungi (Blast. dermatitidis, Coccidioides spp., Hist. capsulatum, Pen. marneffei, and Spor. schenckii), molds (Aspergillus spp., Mucor spp., Rhizomucor spp. and Rhizopus spp.), some dematiaceous fungi and yeasts (Candida spp. and Cryptococcus spp.).
  • General DescriptionTechnetium (99mTc) exametazime is a mixture of unstablelipophilic enantiomers that rapidly cross the blood-brain barrierand is trapped in the tissues. The proposed trapping mechanismfor localization includes reduction by glutathione. Asimilar diffusion and trapping process occurs with autologouslymphocytes in vitro.
    Exametazime is also known as hexamethylpropyleneamineoxime or HMPAO. The radiolabeled complex is indicated for cerebral perfusion in stroke, but is most commonlyused for the radiolabeling of autologous leukocytesas an adjunct in the localization of intra-abdominal infectionand inflammatory bowel disease.
    Each kit includes several components: (a) reaction vialscontaining a mixture of exametazime, stannous chloride,and sodium chloride; (b) vials of 1% methylene blue; (c)vials of phosphate buffer in 0.9% NaCl; and (d) 0.45-μm syringefilters. Product preparation depends on the intendeduse.
  • Pharmaceutical ApplicationsA synthetic triazole available for oral administration.
  • PharmacokineticsCmax 200 mg oral: 0.5 mg/L after 4 h
    Plasma half-life: 35 h
    Volume of distribution: 1774 L
    Plasma protein binding: >98%
    Absorption
    Oral absorption is slow. Absorption from the gastrointestinal tract is improved if the drug is given with a high-fat meal. Blood concentrations increase in proportion to dosage up to 800 mg.
    Distribution
    It is extensively distributed into body tissues.
    Metabolism and excretion
    It is not as extensively metabolized by the hepatic cytochrome P450 system as other triazole antifungals. More than 70% of an administered dose is eliminated in the feces, predominantly as unchanged drug. The remainder is excreted as glucuronidated derivatives in the urine. Posaconazole is a substrate for intestinal P-glycoprotein,an adenosine triphosphate-dependent plasma membrane transporter responsible for drug efflux from cells. Multiple peaks in blood concentrations have been observed, suggesting that effluxed drug is reabsorbed into the systemic circulation.
  • Clinical UseInvasive aspergillosis
    Fusarium infection
    Chromoblastomycosis and mycetoma
    Coccidioidomycosis
    Oropharyngeal candidosis
    Prophylaxis of invasive fungal infections in patients at serious risk
    With the exception of oropharyngeal candidosis and prophylaxis, use is presently restricted to patients with disease that is refractory to other antifungal drugs, or who are intolerant to them.
  • Side effectsIt is generally well tolerated even for long periods. Unwanted effects include gastrointestinal discomfort and mild to moderate, transient abnormalities of liver enzymes. Rare side effects include cholestasis and hepatic failure.
  • Chemical SynthesisSeveral routes to the synthesis of posaconazole have been published in the literature. The most likely route to large scale synthesis uses convergent synthesis of a key chiral THF subunit 101 and aryl piperazine amine 102 followed by introduction of the triazole subunit at the end.The readily accessible allyl alcohol 94 was brominated (PBr3) to give bromide 95 which was alkylated with sodium diethylmalonate and the resulting diester was reduced with NaBH4/LiCl, to give the key diol 97 in very good yields. After scanning many hydrolases to desymmetrize the diol via selective acylation, hydrolase SP 435 was found to be suitable. Thus reaction of the diol 97 in the presence of SP 435 with vinyl acetate in acetonitrile gave monoacetate 98 in greater than 90% yield. Iodine mediated cyclization of the monoacetate 98 with iodine in dichloromethane gave chiral iodide 99 in 86% yield. The iodide was converted to triazole (sodiumtriazole, DMF: DMPU) and immediately followed by hydrolysis of the acetate with sodium hydroxide to provide alcohol 100. Activation of the alcohol to the pchlorobenzene sulfonate 101 proceeded in 76% yield which was then coupled with commercially available amino alcohol piperazine 102 with aqueous sodium hydroxide in DMSO to give amine intermediate 103 in 96% yield. The amine was reacted with benzoyl chloride to give benzoate 104 (97%), which was subsequently converted to triazine of posaconazole.
    For the preparation of chiral hydrazine 107, intermediate needed to make the triazolone, lactam 105 was reduced with Red-Al to give (S)-2-benzyloxy propanal 106 (94%) which was then reacted with formyl hydrazine to give hydrazone 107 in 81% yield. Addition of EtMgBr directly to formyl hydrozones 107 gave mixture of (S,S)stereoisomer 109 and (S,R)-diastereomer 110 in relative good diastereoselectivity (94:6) in 55% yield. However, protection of the formyl group as TBDMS ether 108 followed by treatment of the EtMgCl gave 95% yield of the (S,S)-diastereomer 109 and (S,R)-diastereomer 110 in 99:1 ratio.
    For finishing off the synthesis, the formyl hydrazine 109 was coupled with the phenyl carbamate 104 in toluene at 75 - 85°C for 12 – 24 hrs. After the completion of coupling, the intermediate was heated at 100 – 110°C for 24 – 48 hrs to completely cyclize to the benzyloxy triazolone 108, which was deprotected with 5% Pd/C and formic acid at room temperature overnight and 40°C for 24 h to give posaconazole (XV) in 80% overall yield.        QQ截图20210210144042.jpg
Posaconazole(171228-49-2)Related Product Information
PosaconazoleSupplierMore
  • Company Name:Tianjin Chempharmatech Co.,Ltd. Gold
  • Tel:022-66211079-
  • Email:sales@chempharmatech.com
  •  
  • Company Name:Beijing Zhongshuo Pharmaceutical Technology Development Co., Ltd Gold
  • Tel:13801208576 010-64430626-
  • Email:maggie@chinazhongshuo.com;sales.1@chinazhongshuo.com
  •  
  • Company Name:INTERCHEMIE NANJING PHARMATECH CO., LTD Gold
  • Tel:13656237714
  • Email:xiaokunfu@126.com QQ374216861;
  •  
  • Company Name:Nanjing NingFan Pharm-Tech CO. LTD. Gold
  • Tel:17368696818
  • Email:info@njnfpharm.com
  •  
  • Company Name:Tianjin shijia biomedical technology co., LTD Gold
  • Tel:QQ:411316762
  • Email:tjshj1212@163.com
  •